The New York Times – Business:
The fallout from the F.D.A.’s rejection of MDMA-assisted treatment for PTSD worries researchers and experts who fear other psychedelic drugs in the pipeline could be jeopardized.
This post first appeared in The New York Times – Business. Read the original article.